With the ever-increasing pace of biological research, there is a plethora of headlines describing novel and fascinating discoveries about our natural world. What’s easy to overlook, however, is the ...
Harmonizing immunophenotyping assay designs facilitates integrating findings across trials, enabling biomarker identification and validation, revealing cohort-specific features and drug mechanisms as ...
Phase II Trial of TAS-102 in Colorectal Cancer Patients With Circulating Tumor DNA-Defined Minimal Residual Disease After Adjuvant Therapy: INTERCEPT-TT A multiplex QIF assay was optimized on tissue ...
Basal cell carcinoma has low immunogenicity. Tumor cells express Foxc1 protein (red), which suppresses HLA class I (green) in the tumor cells. Compromised antigen presentation ranks among the top ...
T cell therapy anitocabtagene autoleucel (anito-cel) continued to show strong results in treating relapsed/refractory ...
Vancouver, British Columbia--(Newsfile Corp. - April 23, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback